ARCHIVES

Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: New Presidents Take Office At ONS, ONCC, ARS; Baird Wins Awards; New VP In Houston

July 8, 1994

The Lancet Oncology Retracts Potti Paper, NEJM Doesn’t

February 4, 2011

NCI director apologizes to cancer centers for inaction on working group report.

October 31, 2003

In Brief: NCI Will Stop Free Group C distribution Of VP-16 Sept. 1 Unless Bristol Supplies It At No Charge

June 25, 1982

Bristol-Myers Cancer Scientist Award Nominations To Close March 1

February 24, 1978

Quality Oncology Wins Pilot Contract For Cancer Management In Fla.

July 27, 2001